Drug application
DAPAGLIFLOZIN; SAXAGLIPTIN (DAPAGLIFLOZIN;SAXAGLIPTIN)
Drugs@FDA ANDA 211565 · GLENMARK GENERICS
Key facts
| Drug name | DAPAGLIFLOZIN; SAXAGLIPTIN |
|---|---|
| Active ingredients | DAPAGLIFLOZIN;SAXAGLIPTIN |
| Application type | ANDA |
| Application number | 211565 |
| Company | GLENMARK GENERICS |
| Dosage forms | UNKNOWN |
| Strength | UNKNOWN |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission status date | Apr 27, 2020 |
At a glance
- 1–9 Submissions
- None Label versions
- None Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.